Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol 1997 ad/promo budget increases by 15%-20% over 1996; focus will be Pravachol.

Executive Summary

BRISTOL 1997 AD/PROMO BUDGET UP 15%-20% OVER 1996, primarily to increase support for the HMG-CoA reductase inhibitor Pravachol, Bristol-Myers Squibb VP-Investor Relations Tim Cost said at a recent Alex. Brown conference in Baltimore. The $300 mil. increase in advertising and promotional activities in 1997 is "primarily being driven by direct-to-consumer and launch costs inside the Pravachol world," Cost said. In 1996, BMS spent about $21.3 mil. on DTC support for Pravachol, while Merck's Zocor was backed with $40.8 mil. in DTC spending, according to Competitive Media Reporting data ("The Pink Sheet" March 24, p. 18).
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS030312

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel